This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Salyrgan, which is sodium [o(hydroxymercuricmethoxypropylcarbamyl) phenoxy] acetate, was accepted by the Council (The Journal, Dec. 22, 1928, p. 1995) on evidence presented by the manufacturer, the Winthrop Chemical Company, of its usefulness as a mercurial diuretic. In 1937 the firm presented as a dosage form Suppositories Salyrgan of the following composition: salyrgan 0.4 Gm., corn starch 0.1 Gm., and cocoa butter 1.3 Gm. Since the rectal administration of a mercurial diuretic seemed rational, the Council accepted Salyrgan Suppositories as a dosage form of Salyrgan, and the description was published in The Journal, May 15, 1937, page 1715. For the same reason the Council accepted Mercurin Suppositories, 0.5 Gm., distributed by the Campbell Products, Inc., and its description was published in The Journal, July 10, 1937, page 133. Mercurin is a mixture of 20 per cent of the β-methoxy-γ-hydroxymercuri-propylamide of trimethyl cyclopentane dicarboxylic acid and 80 per cent of its sodium
SALYRGAN SUPPOSITORIES AND MERCURIN: A WARNING and ACCEPTANCE OF SALYRGAN SUPPOSITORIES RESCINDED. JAMA. 1939;113(3):213–214. doi:10.1001/jama.1939.72800280007008
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: